drugset

drugset / Trial / NCT01303497

Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

NCT01303497 ↗

Phase 2 Completed 70 enrolled Centre Oscar Lambret French Sarcoma Group · collab Study Group of Bone Tumors · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Efficacity of Paclitaxel in association or not with Bevacizumab in treatment of angiosarcoma

Timeline

Start: 2010-09-10
Primary completion: 2014-04
Completion: 2019-01-29

Publications

Lebellec L, Bertucci F, Tresch-Bruneel E, Ray-Coquard I, Le Cesne A, Bompas E, Blay JY, Italiano A, Mir O, Ryckewaert T, Toiron Y, Camoin L, Goncalves A, Penel N, Le Deley MC. Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. BMC Cancer. 2018 Oct 11;18(1):963. doi: 10.1186/s12885-018-4828-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Paclitaxel	Small molecule	90 mg/m2	Intravenous

Indications